Suryasarathi Dasgupta
Director - Scientific & Precision Medicine Immunology Abbvie
Seminars
Wednesday 4th November 2026
Redefining the Oral Psoriasis Market: Positioning Next-Generation TYK2 Inhibitors to Compete with Biologics on Efficacy, Convenience & Durability
3:00 pm
- Demonstrating biologic-like PASI 90 and PASI 100 responses from a once-daily oral TYK2 inhibitor, to position next-generation oral therapies against injectable standards of care
- Assessing rapidity, durability and complete skin clearance outcomes across TYK2 programs, clarifying what level of efficacy is now required for differentiation in psoriasis, to strengthen competitive positioning in an increasingly crowded inflammatory dermatology market
- Understanding how regulators, physicians and payers may evaluate highly selective oral TYK2 inhibition versus established biologics and oral competitors such as Otezla and Sotyktu, aligning clinical development with commercial expectations, to maximize uptake, reimbursement and long-term franchise value
